Startups
Pilatus Biosciences pioneers innovative therapies using first-in-class antibodies and bifunctional proteins to target metabolic checkpoints, reprogramming the immune microenvironment to address cancer and immune-related diseases.
Overview
Location
Switzerland
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 7, 2026 | Three Swiss biotechs widen their reach into pharma, paediatrics and lung disease | SOPHiA GENETICS, a Rolle (VD)-based genomics company founded in 2011, runs SOPHiA DDM, a cloud platform that analyses genomic and multimodal data for hospitals, laboratories and biopharma partners. The company reported second-quarter reven... |
| Jul 23, 2026 | Pilatus Biosciences expands into Hong Kong with subsidiary and clinical trial | PLT012 is a first-in-class therapeutic targeting CD36, a key regulator of metabolic dysfunction and inflammation. The program is being developed for indications where modulation of CD36 has the potential to improve patient outcomes. The st... |
| Mar 19, 2026 | Swiss biotechs advance clinical programs across multiple therapeutic areas | Pilatus Biosciences, a startup based in Vaud, is developing novel immunotherapies for liver and gastrointestinal cancers. Founded in 2022 from the Ludwig Institute for Cancer Research and supported by the Cancer Research Institute, Pilatus... |
| Aug 15, 2025 | Pilatus Biotech to launch first-in-human trials | PLT012 is Pilatus’ lead immunomodulatory candidate designed to reprogram the fibrotic and immunosuppressive tumor microenvironment (TME) characteristic of HCC. HCC is the most common type of primary liver cancer and remains one of the lead... |
| Apr 15, 2025 | Pilatus Biosciences to Present Research on PLT012 at AACR 2025 | Novel Immunometabolism Approach Targets Immune-Cold Solid Tumors DOVER, Del. and EPALINGES, Switzerland, April 15, 2025 /PRNewswire/ -- Pilatus Biosciences, pioneering biologics targeting metabolic checkpoints, will present new research on ... |
| Dec 11, 2024 | Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment | DOVER, Del. and EPALINGES, Switzerland, Dec. 11, 2024 /PRNewswire/ -- Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treatin... |
| Dec 3, 2024 | Biotech startups celebrate new achievements | AC Immune, a biopharmaceutical company focused on neurodegenerative diseases, has reported positive interim results from its Phase 2 VacSYn clinical trial evaluating ACI-7104.056, an active immunotherapy targeting alpha-synuclein for early... |
Reviews 0
FAQ about Pilatus Biosciences
What has the press written about Pilatus Biosciences?
Parsers VC has collected 8 articles mentioning Pilatus Biosciences, among them “Three Swiss biotechs widen their reach into pharma, paediatrics and lung disease” (Aug 7, 2026) and “Pilatus Biosciences expands into Hong Kong with subsidiary and clinical trial” (Jul 23, 2026).
Is Pilatus Biosciences still active?
Yes, Pilatus Biosciences is active; its latest activity on Parsers VC dates from Nov 2, 2026.